These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 11842755

  • 1. Hormone therapy in advanced prostate cancer.
    Forster TH, Stoffel F, Gasser TC.
    Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
    [No Abstract] [Full Text] [Related]

  • 2. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.
    Bolla M, de Reijke TM, Zurlo A, Collette L.
    Front Radiat Ther Oncol; 2002; 36():81-6. PubMed ID: 11842758
    [No Abstract] [Full Text] [Related]

  • 3. Endocrine therapy of prostate cancer.
    Bare RL, Torti FM.
    Cancer Treat Res; 1998; 94():69-87. PubMed ID: 9587683
    [Abstract] [Full Text] [Related]

  • 4. Intermittent androgen ablation as a treatment for prostate cancer.
    Wolff JM.
    Front Radiat Ther Oncol; 2002; 36():66-71. PubMed ID: 11842756
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
    Ryan CJ, Small EJ.
    Urology; 2003 Dec 29; 62 Suppl 1():87-94. PubMed ID: 14747046
    [Abstract] [Full Text] [Related]

  • 8. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
    Hellerstedt B.
    Urology; 2003 Dec 29; 62 Suppl 1():79-86. PubMed ID: 14747045
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Neoadjuvant androgen suppression and external beam radiation therapy.
    Zietman AL, Smith CT.
    Front Radiat Ther Oncol; 2002 Dec 29; 36():87-98. PubMed ID: 11842759
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A.
    Arch Esp Urol; 2002 Sep 29; 55(7):771-5. PubMed ID: 12380304
    [No Abstract] [Full Text] [Related]

  • 15. Innovations in the systemic therapy of prostate cancer.
    Shepard DR, Raghavan D.
    Nat Rev Clin Oncol; 2010 Jan 29; 7(1):13-21. PubMed ID: 19997075
    [Abstract] [Full Text] [Related]

  • 16. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F, Dupont A, Belanger A.
    Important Adv Oncol; 1985 Jan 29; ():193-217. PubMed ID: 3916740
    [No Abstract] [Full Text] [Related]

  • 17. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
    Pinto F, Calarco A, Totaro A, Sacco E, Volpe A, Racioppi M, D'Addessi A, Bassi PF.
    Urologia; 2010 Jan 29; 77(2):71-83. PubMed ID: 20890863
    [Abstract] [Full Text] [Related]

  • 18. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S, Akaza H.
    Gan To Kagaku Ryoho; 2001 Jul 29; 28(7):917-26. PubMed ID: 11478140
    [Abstract] [Full Text] [Related]

  • 19. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
    Matsushima H, Goto T, Hosaka Y, Kitamura T, Kawabe K.
    Cancer; 1999 Apr 15; 85(8):1822-7. PubMed ID: 10223578
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.